Get the Stockscreener App
1.985
3.88%
-0.0802
After Hours:
1.99
0.005
+0.25%
Adlai Nortye Ltd Adr stock is traded at $1.985, with a volume of 28,004.
It is down -3.88% in the last 24 hours and down -29.94% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$2.0652
Open:
$1.9
24h Volume:
28,004
Relative Volume:
3.11
Market Cap:
$72.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.7878
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
-10.99%
1M Performance:
-29.94%
6M Performance:
-77.64%
1Y Performance:
-86.77%
1-Day Range:
$1.8864
$2.11
1-Week Range:
$1.8864
$2.27
52-Week Range:
$1.8864
$17.48
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
H.C. Wainwright sees upside in Adlai Nortye stock amid robust oncology pipeline - Investing.com
Adlai Nortye Reports Strong 2024 Mid-Year Results - TipRanks
Adlai Nortye releases unaudited H1 2024 results, adds new director - Investing.com
Adlai Nortye Announces Executive Leadership Transition - TipRanks
Closing Bell Recap: Adlai Nortye Ltd. ADR (ANL) Ends at 7.70, Reflecting a -6.78 Downturn – DWinneX - The Dwinnex
Adlai Nortye to Unveil Cancer Drug Data at ASCO 2024TipRanks.com - TipRanks
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewswire Inc.
Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year? - Yahoo Finance Australia
Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year? - Yahoo Finance
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday By Benzinga - Investing.com UK
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Model N, Ducommun, Perpetua Resources And Other Big Stocks Moving Higher On Monday - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO (Pending:ANL) - Seeking Alpha
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):